Closing the Medical Cannabis Value Chain Loop
by Michael Kryton, EQUITY IR contributing writer
GCAC (CSE: APP, FSE: 2FA), the winner of the 2019 A.I of the Year Award at the prestigious 2019 Malta Medical Cannabiz Awards in early November, continues to push innovation in the medical cannabis sectors to new levels. They refer to their new vision as Cannabis 3.0 and they’re team just got larger to harness this vision.
GCAC has also penned agreements with two companies. Intelligenta is an Israel based start-up developing wearable sensor technology that monitors the effect of cannabis on patients and allows highly accurate recommendations of their treatment journey. The privately held JV will combine the IPs of both entities free of charge in exchange for equity positions. Debt instruments in the LOI will help GCAC (who owns 51 percent of the JV) maintain control as they move to a predetermined evaluation of $30 million.
“We have structured this partnership to maximize the creation of a fully scalable 360° data aggregation model through joining our advanced technologies. The technology solution will have no limitations where it can be used, can meet any global regulatory requirements and used by all cannabis industry participants in the value proposition chain,” said Brad Moore, CEO of GCAC “We believe it’s a true embodiment of the term Cannabis 3.0.”
The second agreement is with Barak Ha’aretz Global (“BG”), a privately held medical cannabis growing operation also in Israel.
Some back story to Cannabis 3.0. Cannabis 1.0 refers to the beginning chapters of medical marijuana, a time of legislative changes, which included legalization. Cannabis 2.0 was a period of standardization during which focus was placed on every aspect from growing and manufacturing to tracking a product from its origin to point-of-sale. It was during this phase that GCAC (Global Cannabis Application Corp) focused on the effects of cannabis beyond the 2.0 matrix. Cannabis 3.0 would encompass patient efficacy tracking.
Given the comprehensive performance of GCAC’s award winning ‘Pain to Strain’ algorithmic intelligence-based consumer biometric feedback system, GCAC was prepared to use the data they collected and report the user experience back to pharmacies, doctors, policy makers, regulators and growers.
Brad Moore knows how important efficacy tracking will be to the industry. “This is critical to the further development of medical cannabis, because the more everyone knows, the sooner things can move forward. For example, regulators like the FDA (Federal Drug Administration) have delayed the approval of current medicinal products because they don’t have enough evidence of the product’s efficacy. Cannabis 3.0 will change that.”
To be clear, the regime of products covers a broad spectrum including (but not limited to) everything from edibles, vapes and skin lotions to drinks and pills. The challenge is identify the active pharmaceutical ingredients and how they work on users. Given the volatility of reports about the variables associated with cannabis, such as CBD, the marketplace remains somewhat confused.
GCAC’s Cannabis 3.0 is the opportunity to increase the competency of the products. Based on patient feedback, the tangible and measureable data will reveal the products that have earned higher ranking. This, of course, serves to imbue a cannabis brand with a strong value based on quality and efficacy.
“Cannabis 3.0 is where individual opinions, biometric tracking, and tracing of the product from its origin meet brand recognition of these products in the marketplace,” says Moore. “Therefore, we will have the answers when someone asks, who has the best strain of medical cannabis? Who has the best CBD oil for headaches, knees, joint pain, or anxiety? Individuals will have the ability to verify real time data, opinions, and other facts about the market.
Enter Citizen Green. GCAC’s system harnesses big data and machine learning solutions, such as Citizen Green Prescriptii Patient Care Solution, to determine the effectiveness of a strain, which ultimately allows them to separate the “gimmicks” from the truly effective strains being produced.
This is good news for growers because they can use the data to develop products that respond to customized needs. This fits perfectly in the Internet of Everything and transforms that context into the Internet of Individuality. GCAC is already ahead of that curve with Citizen Green.
About the Citizen Green App. (Yes, there’s an app for that.) The app enables patients to inform themselves before going to a pharmacy. It reviews the brands or strains that are recommended for an individual including how they fit a personal treatment journey, and its expected effects, based on the user’s biometrics, medical history, and medications, from home province, state, or continent. The result is a more reliable and effective personal treatment, not to mention the impact it has on consumer trust. It all adds up to consumer brand recognition and Citizen Green is getting much attention as a result, even from healthcare professionals.
For Brad Moore, Citizen Green is far more than just an app. “It’s a fully integrated system that feeds on consumer input. It brings together a biometric watch from Intelligenta together with an AI engine and the blockchain. And, because GCAC is actually defining Cannabis 3.0 with a technology workflow, it creates a greater system of information and analysis that transcends the app.”
This idea of system versus app has major implications. Doctors now have the ability to view real time data and make real-time recommendations based on quantitative and qualitative information on users and the proper delivery of patient care and consumer protection. On the patient side, it will help increase reliability and restore peoples’ trust in doctors writing prescriptions using brand and strain specific information based on real-time data and clinical information.
Within the GCAC and Intelligenta partnership, GCAC will contribute its Citizen Green Patient Care Solution and Intelligenta will provide its proprietary biometric watch. Nadav Segal, the CEO of Intelligenta, said, “Integrating our biometric watch that creates nine data points every ten seconds with GCAC’s award winning AI and storing processed data on an immutable blockchain is an incredible opportunity for both companies, the cannabis industry, shareholders and most importantly patients themselves.”
The combined technology solution will map a wide range of feedback provide by Intelligenta’s biometric user watch and user inputs in the Prescriptii mobile and retail apps.
GCAC, who continues to assert new patents within the cannabis medical sector, is already recognized for the ecosystem it is developing and serving. Within the Cannabis 3.0 paradigm, distortions in medical prognosis can be resolved, creating confidence in prescribing medical cannabis for aliment treatment. As a result, consumer and retailer confidence will grow. Products will get better. Certainly, the integration of Citizen Green and Intelligenta’s biometric watch is a step in that direction.
By the time Cannabis 4.0 comes around, the cannabis industry will have moved far beyond the era when cannabis was mired in Reefer Madness, in large part thanks to the innovations of GCAC and Intelligenta.
About Global Cannabis Applications Corp.
Global Cannabis Applications Corp. is a global leader in designing, developing, marketing and acquiring innovative data technologies for the medical cannabis industry. The Citizen Green platform is the world’s first end-to-end – from patient to regulator – medical cannabis data solution. It uses six core technologies: mobile applications, artificial intelligence, regtech, smart databases, blockchain and digital reward tokens, to qualify candidates for clinical studies. These technologies facilitate the proliferation of digital conversations by like-minded people in the medical cannabis community. Managed by digital and cannabis industry experts, GCAC is focused on viral global expansion by providing the best digital experience in the cannabis market.
Intelligenta is an Israel based start-up developing wearable sensor technology that monitors the effect of cannabis on patients and allows highly accurate recommendations of their treatment journey. Intelligenta was founded by Mr. Nadav Segal, an accomplished entrepreneur in the cannabis technology sector in Israel, one of the founders of P.S.C-CAN https://www.psc-grp.com/, a fully integrated international seed to product Hemp company. Intelligenta’s solution is based on a cutting edge Israeli developed sensor watch, which monitors thousands of reliable cardiac and blood pressure data points per patient, 24hrs-7 days, and which clinical trials showed it to be as precise as ECG monitoring. The watch is currently in the advanced stages of FDA and CE certification.